10x Genomics (TXG)
(Delayed Data from NSDQ)
$21.25 USD
-1.72 (-7.49%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $21.26 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Income Statements
Fiscal Year end for 10x Genomics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 619 | 516 | 490 | 299 | 246 |
Cost Of Goods | 209 | 120 | 74 | 58 | 61 |
Gross Profit | 409 | 396 | 416 | 240 | 185 |
Selling & Adminstrative & Depr. & Amort Expenses | 675 | 564 | 469 | 775 | 215 |
Income After Depreciation & Amortization | -265 | -168 | -52 | -534 | -31 |
Non-Operating Income | 17 | 6 | -1 | 1 | 3 |
Interest Expense | 0 | 0 | 1 | 2 | 3 |
Pretax Income | -249 | -162 | -54 | -534 | -31 |
Income Taxes | 6 | 4 | 5 | 8 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -255 | -166 | -58 | -543 | -31 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -255 | -166 | -58 | -543 | -31 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -222 | -134 | -24 | -515 | -24 |
Depreciation & Amortization (Cash Flow) | 44 | 34 | 28 | 19 | 7 |
Income After Depreciation & Amortization | -265 | -168 | -52 | -534 | -31 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 117.17 | 113.86 | 110.35 | 101.15 | 39.09 |
Diluted EPS Before Non-Recurring Items | -1.66 | -1.46 | -0.53 | -0.95 | -0.80 |
Diluted Net EPS (GAAP) | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 |
Fiscal Year end for 10x Genomics falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 153.10 | 141.01 | 183.98 | 153.64 | 146.82 |
Cost Of Goods | 48.88 | 48.09 | 68.20 | 58.12 | 47.21 |
Gross Profit | 104.22 | 92.91 | 115.78 | 95.53 | 99.61 |
SG&A, R&D, and Dept/Amort Expenses | 145.96 | 154.41 | 170.96 | 190.33 | 162.97 |
Income After SG&A, R&D, and Dept/Amort Expenses | -41.74 | -61.50 | -55.18 | -94.80 | -63.36 |
Non-Operating Income | 4.66 | 3.70 | 8.60 | 3.05 | 2.60 |
Interest Expense | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
Pretax Income | -37.08 | -57.80 | -46.60 | -91.74 | -60.77 |
Income Taxes | 0.82 | 2.15 | 2.35 | 1.24 | 1.65 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -37.90 | -59.95 | -48.95 | -92.99 | -62.41 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -37.90 | -59.95 | -48.95 | -92.99 | -62.41 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 120.07 | 119.39 | 118.57 | 117.73 | 116.71 |
Diluted EPS Before Non-Recurring Items | -0.32 | -0.50 | -0.41 | -0.51 | -0.53 |
Diluted Net EPS (GAAP) | -0.32 | -0.50 | -0.42 | -0.79 | -0.53 |